Announcement • May 14
Versarien plc has completed a Follow-on Equity Offering in the amount of £0.425 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £0.425 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,545,454,545
Price\Range: £0.000275
Transaction Features: Subsequent Direct Listing Announcement • Mar 27
Versarien plc, Annual General Meeting, Apr 28, 2025 Versarien plc, Annual General Meeting, Apr 28, 2025. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom Announcement • Jan 29
Versarien plc has completed a Follow-on Equity Offering in the amount of £0.246038 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £0.246038 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 745,569,784
Price\Range: £0.00033
Transaction Features: Subsequent Direct Listing Announcement • Dec 10
Versarien plc Announces the Launch of New Biosensors Versarien Plc announced the launch of a new biosensor chip utilising novel graphene barristor sensor platform technology. These graphene barristor devices, developed in South Korea by A Barristor Company ("ABC"), will utilise chemical vapour deposition ("CVD") grown graphene, that is produced under a Versarien licence. Versarien has signed a distribution agreement with ABC to distribute the products in the UK and Europe. A barristor (triode device) is a new type of graphene-based transistor with a Schottky barrier between graphene and silicon. The current modulation is amplified more than 10,000 times compared to graphene field-effect transistors ("GFET") enabling the barristor transistors to overcome many GFET limitations. In these new products, the graphene surface is terminated with either pyrenebutanoic acid succinimidyl ester ("PBASE") or a customer preferred linker. PBASE is one of the most frequently used linkers for the surface modification of field-effect transistor (FET) biosensors based on carbon nanotubes and graphene. The products can be supplied as individual chips or on a wafer scale. It is expected that the CVD graphene used in the products will be supplied by MCK Tech Co. Ltd. ("MCK Tech") in South Korea, which is an existing Licensing partner of Versarien, and it will also undertake some of the device fabrication. The range of sensor products to be distributed by Versarien may be expanded at a later date based on ABC's product developments, such as in infrared detection, gas/chemical detection, temperature detection or multiple sensor on a chip technology. Announcement • Sep 30
Harper Bennett Limited completed a binding agreement to acquire AAC Cyroma Limited from Versarien plc (AIM:VRS) for £0.55 million. Harper Bennett Limited completed a binding agreement to acquire AAC Cyroma Limited from Versarien plc (AIM:VRS) for £0.55 million on September 30, 2024. The consideration of £0.55 million is payable in cash, in 16 equal quarterly instalments of £0.0034 million, commencing three months from completion. Versarien will retain a charge over the assets of AAC Cyroma and Harper Bennett Limited to cover any outstanding consideration payable. In the financial year ended 30 September 2023 AAC Cyroma incurred a loss of £0.146 million and had net assets at 30 September 2023 of £0.411 million. The disposal of AAC Cyroma is in line with the Company's strategy to focus on its core graphene technology and divesting of its mature businesses. The proceeds of the disposal will be used for the Company's general corporate and working capital purposes. Matthew Johnson, Adam Cowl of SP Angel Corporate Finance LLP acted as financial advisor for Versarien plc. Announcement • Jul 25
Versarien plc has completed a Follow-on Equity Offering in the amount of £0.55 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £0.55 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 846,153,845
Price\Range: £0.00065
Transaction Features: Subsequent Direct Listing New Risk • Jun 07
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£1.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (77% average daily change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (460% increase in shares outstanding). Market cap is less than US$10m (€1.42m market cap, or US$1.54m). Announcement • Mar 29
Versarien plc, Annual General Meeting, Apr 30, 2024 Versarien plc, Annual General Meeting, Apr 30, 2024, at 09:30 Coordinated Universal Time. Location: Riverbank House, 2 Swan Lane London United Kingdom Reported Earnings • Mar 28
Full year 2023 earnings released: UK£0.055 loss per share (vs UK£0.027 loss in FY 2022) Full year 2023 results: UK£0.055 loss per share (further deteriorated from UK£0.027 loss in FY 2022). Revenue: UK£5.45m (down 26% from FY 2022). Net loss: UK£13.5m (loss widened 156% from FY 2022). Announcement • Mar 21
Versarien plc has completed a Follow-on Equity Offering in the amount of £0.615 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £0.615 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 492,000,000
Price\Range: £0.00125
Transaction Features: Subsequent Direct Listing Announcement • Jan 19
Versarien plc has completed a Follow-on Equity Offering in the amount of £0.4 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £0.4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 500,000,000
Price\Range: £0.0008
Transaction Features: Subsequent Direct Listing New Risk • Dec 26
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (93% average daily change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (156% increase in shares outstanding). Market cap is less than US$10m (€1.27m market cap, or US$1.40m). Minor Risk Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Announcement • Nov 09
Versarien plc has completed a Follow-on Equity Offering in the amount of £0.454822 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £0.454822 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 165,389,817
Price\Range: £0.00275
Transaction Features: Subsequent Direct Listing New Risk • Jul 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 70% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£4.9m free cash flow). Share price has been highly volatile over the past 3 months (86% average daily change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (70% increase in shares outstanding). Market cap is less than US$10m (€5.13m market cap, or US$5.76m). Reported Earnings • Jun 10
First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.011 loss in 1H 2022) First half 2023 results: UK£0.015 loss per share (further deteriorated from UK£0.011 loss in 1H 2022). Revenue: UK£2.62m (down 33% from 1H 2022). Net loss: UK£3.20m (loss widened 55% from 1H 2022). Announcement • May 19
Versarien plc Provides an Update on the Trials of Versarien's Water-Based Graphene Admixture, CementeneTM in Precast Concrete Mixs That Have Been Carried Out by Banagher Precast Concrete Limited Versarien plc provided an update on the trials of Versarien's water-based graphene admixture, CementeneTM in precast concrete mixes that have been carried out by Banagher Precast Concrete Limited ("Banagher"), a precast concrete manufacturer and supplier of precast concrete products to the civil engineering and construction industries throughout the UK and Ireland. The Company reported that preliminary results from the work undertaken by Banagher have demonstrated that 20% of ordinary Portland cement ("OPC") can be removed from Banagher's typical precast concrete mix when CementeneTM is added, whilst maintaining the compression strength of the concrete. These initial results demonstrate the significant potential to reduce CO2 emissions without impacting the performance of the concrete. The production of 1 kg of CementeneTM is estimated to generate approximately 1.44 kg of CO2 emissions and approximately 5 kg of Cementene TM is used per cubic metre of concrete. The production of 1 km of OPC emits approximately 0.8 kg of CO2 and c.500 kg of OPC is used per cubic metre of Banagher's precast concrete. Therefore, the removal of 20% of OPC in the precast concrete mix (approximately 100 kg) equates to a net saving of approximately 72.8 kg of CO2 emissions per cubic metre of concrete poured. Based on Banagher's average 60,000 cubic metre output of concrete per year, the savings achieved in these trials mean that the incorporation of CementeneTM could offer almost 4.4 million kg of CO2 savings per year at a cost the Company believes is competitive for this level of emissions reduction. Reported Earnings • Feb 26
Full year 2022 earnings released: UK£0.028 loss per share (vs UK£0.035 loss in FY 2021) Full year 2022 results: UK£0.028 loss per share (improved from UK£0.035 loss in FY 2021). Revenue: UK£7.40m (down 3.6% from FY 2021). Net loss: UK£5.29m (loss narrowed 19% from FY 2021). Revenue is forecast to stay flat during the next 3 years compared to a 1.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Announcement • Dec 07
Versarien plc has completed a Follow-on Equity Offering in the amount of £1.85 million. Versarien plc has completed a Follow-on Equity Offering in the amount of £1.85 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 18,500,000
Price\Range: £0.1
Transaction Features: Subsequent Direct Listing Board Change • Nov 21
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Chairman Savory Hill was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Aug 25
Versarien plc, Annual General Meeting, Sep 30, 2022 Versarien plc, Annual General Meeting, Sep 30, 2022, at 09:00 Coordinated Universal Time. Location: Gloucester Rugby, Kingsholm Stadium Kingsholm Road, Kingsholm, Gloucester, GL1 3AX Gloucester, United Kingdom Announcement • Jun 28
Versarien plc Announces Launch of New Superparamagnetic Material Versarien plc announced the launch of a new hybrid nanomaterial that has superparamagnetic properties, which can be used across a range of applications, such as in defence and healthcare. The development of the material has been led by Versarien's 62% owned subsidiary, Gnanomat S.L. (Gnanomat), whose research has pioneered the generation of a new family of versatile nanocomposites based on graphene and other forms of carbon, combined with metal or metal oxide nanoparticles typically intended for energy storage applications. The superparamagnetic material combines graphene with both iron oxide and manganese oxide nanoparticles that provide the material with magnetic properties. In return, graphene provides electrical conductivity to these electrically insulating metal oxides. Magnetic nanocomposites can readily respond to external magnetic fields which allow them to be manipulated. Potential applications of the material include the treatment of wastewater whereby pollutants are adsorbed onto the graphene surface. The material also lends itself to biomedical and biotechnology applications, or defence applications requiring the shielding of electromagnetic fields. Magnetic manipulation could allow the recovery and recycling of the graphene, something that could not be done with normal graphene compounds. Reported Earnings • May 13
Full year 2022 earnings released: UK£0.026 loss per share (vs UK£0.045 loss in FY 2021) Full year 2022 results: UK£0.026 loss per share (up from UK£0.045 loss in FY 2021). Revenue: UK£7.63m (up 16% from FY 2021). Net loss: UK£4.94m (loss narrowed 37% from FY 2021). Over the next year, revenue is expected to shrink by 21% compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Announcement • May 03
Versarien plc to Report Fiscal Year 2022 Results on May 12, 2022 Versarien plc announced that they will report fiscal year 2022 results on May 12, 2022 Board Change • Apr 29
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Chairman Savory Hill was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Feb 22
Flux Footwear to Launch Graphene Enhanced Shoe Versarien announced that, following a collaboration with Flux Footwear LLC ("Flux"), the Company will be supplying graphene enhanced elastomers to Flux to bring an improved model of Flux's 'Adapt' shoe, the 'AdaptMid', to market. Under the terms of the partnership, the 'Adapt' barefoot athleisure model has been enhanced with Versarien's Graphene-Wear™ technology, following research and testing to improve the rubber outsole, augmenting the shoe's mechanical and physical properties. The new model, the 'AdaptMid', provides greater durability through improved abrasion resistance whilst maintaining the shoe's traction characteristics. This technology has been developed by the Company's in-house technology teams at University of Manchester and University of Cambridge as part of the GSCALE project and has the potential for multiple elastomer projects. Reported Earnings • Dec 08
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: UK£0.015 loss per share (up from UK£0.024 loss in 1H 2021). Revenue: UK£3.82m (up 41% from 1H 2021). Net loss: UK£2.87m (loss narrowed 31% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 39% per year whereas the company’s share price has fallen by 40% per year. Reported Earnings • Aug 06
Full year 2021 earnings released: UK£0.044 loss per share (vs UK£0.027 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: UK£6.57m (down 21% from FY 2020). Net loss: UK£7.78m (loss widened 88% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings. Announcement • Feb 09
Versarien plc Provides Update on Recent Developments with Regard to the company's Graphene Enhanced Face Masks Versarien plc provided an update on recent developments with regard to the company's graphene enhanced face masks. As reported in the company's interim results announced on 21 January 2021, the Company's wholly owned Chinese subsidiary, Beijing Versarien Technology Company Limited, has been working with its partner on further developments of the masks. This included the testing of a prototype second generation graphene enhanced face mask conducted in China at the Analytical and Testing Centre of Capital Regions which showed a 99.92% anti-viral activity rate against the SARS-CoV-2 virus. In a further development, the Company reported that, after testing of prototypes of the latest version of the mask, which is a non-valve mask, it has been certified as meeting the FFP3 standard, the highest standard under the European EN149 standard for filtering half face masks. The FFP3 certification process, included, inter alia, the testing of the packaging, the robustness of the material, its practical performance, total inward leakage, breathing resistance, clogging, compatibility with skin and the carbon dioxide content of the inhalation air. In order to meet the criteria to be certified as a FFP3 mask, the mask had to pass all the relevant tests, including demonstrating less than 2% inward leakage and the filtering of at least 99% of particulate matter. The testing, to the European EN149 standard, has been carried out in China by SGS-CSTC Standards Technical Services Co. Ltd. a joint venture founded in 1991 between SGS Group, a world leading inspection, verification, testing and certification company, and China Standard Science and Technology Group. Recent Insider Transactions • Jan 23
CEO & Executive Director recently sold €1.0m worth of stock On the 21st of January, Neill Ricketts sold around 2m shares on-market at roughly €0.61 per share. This was the largest sale by an insider in the last 3 months. This was Neill's only on-market trade for the last 12 months. Reported Earnings • Jan 23
First half 2021 earnings released: UK£0.025 loss per share The company reported a poor first half result with increased losses and weaker revenues and control over expenses. First half 2021 results: Revenue: UK£3.12m (down 29% from 1H 2020). Net loss: UK£4.16m (loss widened 121% from 1H 2020). Announcement • Jan 08
Versarien plc Appoints Stephen Hodge as Chief Technology Officer Versarien plc announced that Dr. Stephen Hodge has been appointed as the Company's Chief Technology Officer (CTO) and has joined the Company's Board with immediate effect. Dr. Hodge is currently Head of Research at Versarien, a role he has held since July 2018. Prior to this, he was employed as a Principal Engineer at Cambridge Graphene Limited, a supplier of graphene inks and other graphene materials, and a subsidiary of Versarien. He has also held post-doctoral research associate positions at the Cambridge Graphene Centre, a research centre attached to the Department of Engineering at the University of Cambridge, and in the Department of Chemistry at Imperial College London, where he also completed a PhD in Nanomaterial Chemistry. Following Dr. Hodge's appointment, the Company's Board now comprises James Stewart (Non-executive Chairman), Neill Ricketts (CEO), Christopher Leigh (CFO), Stephen Hodge (CTO), Susan Bowen (Non-executive Director) and Iain Gray (Non-executive Director). Is New 90 Day High Low • Jan 05
New 90-day high: €0.52 The company is up 28% from its price of €0.41 on 07 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period. Is New 90 Day High Low • Oct 16
New 90-day low: €0.34 The company is down 18% from its price of €0.42 on 17 July 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. Reported Earnings • Sep 25
Full year earnings released - €0.027 loss per share Over the last 12 months the company has reported total losses of UK£4.15m, with losses widening by 67% from the prior year. Total revenue was UK£8.28m over the last 12 months, down 9.4% from the prior year. Is New 90 Day High Low • Sep 25
New 90-day low: €0.37 The company is down 21% from its price of €0.47 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. Announcement • Jul 18
Versarien plc to Report Fiscal Year 2020 Results on Aug 11, 2020 Versarien plc announced that they will report fiscal year 2020 results on Aug 11, 2020 